SK bio wins Korean Supreme Court backing in Pfizer patent battle
South Korean vaccine maker SK Bioscience has secured a final court victory over US pharma major Pfizer (NYSE: PFE) in a long-running patent dispute concerning exports of its 13-valent pneumococcal conjugate vaccine, SKYPneumo (pneumococcal 13-valent conjugate vaccine).
The Supreme Court of Korea ruled that SK Bioscience’s exports of individual conjugate bulk substances and research-use finished products of SKYPneumo to Russia did not infringe Pfizer’s local patent for Prevnar 13 (pneumococcal 13-valent conjugate vaccine).
The legal outcome clears the way for SK Bioscience to proceed with international business activities previously held back by the litigation. The company now plans to export components of SKYPneumo to countries with high demand for pneumococcal vaccines, particularly in Southeast Asia and Latin America.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze